menu
    • menu
    [{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Chong Kun Dang Pharm \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Chong Kun Dang Pharm","amount2":0.13,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Chong Kun Dang Pharm \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Chong Kun Dang Pharm \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Aclipse Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lobeglitazone","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Aclipse Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Aclipse Therapeutics"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CKD-510","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":1.3100000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3100000000000001,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Chong Kun Dang Pharm

    Menu

    Chong Kun Dang Pharm

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CKD-510

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,305.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule

                            Details : Under the agreement, Novartis will have global exclusive rights to develop and commercialize CKD-510, a small molecule histone deacetylase 6 (HDAC6) inhibitor developed by CKD Pharm worldwide, excluding Korea.

                            Product Name : CKD-510

                            Product Type : Small molecule

                            Upfront Cash : $80.0 million

                            November 07, 2023

                            Lead Product(s) : CKD-510

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,305.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lobeglitazone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Aclipse Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement ...

                            Details : Under the agreement, Aclipse gains worldwide rights to develop CKD’s M107 (lobeglitazone), an oral, small molecule, for gastroparesis and additional indications.

                            Product Name : M107

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 14, 2023

                            Lead Product(s) : Lobeglitazone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Aclipse Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Synaffix

                            Deal Size : $132.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline

                            Details : Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Synaffix

                            Deal Size : $132.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            S. Korea's Nafabeltan gets clinical approval for COVID-19 treatment in Australia

                            Details : The drug, Nafabeltan, will be administered to patients as part of the Australian government-led clinical study to find a COVID-19 treatment. The drug is currently used as a blood anticoagulant and acute pancreatitis treatment.

                            Product Name : Nafabeltan

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2020

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chong Kun Dang Proceeds to Phase 2 Trial in Russia to Treat Covid-19

                            Details : Russia’s Drug Ministry approved of its clinical phase two trial design targeting some 100 seriously afflicted COVID-19 pneumonic patients there. The patients will be administered nafamostat for 10 days.

                            Product Name : Nafabeltan

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 01, 2020

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Namodenoson

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Recipient : Can-Fite BioPharma

                            Deal Size : $8.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Can-Fite Granted Patent Allowance for Namodenoson in South Korea

                            Details : Chong Kun Dang Pharmaceuticals (CKD) of South Korea, has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and NASH.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : $6.0 million

                            February 18, 2020

                            Lead Product(s) : Namodenoson

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Recipient : Can-Fite BioPharma

                            Deal Size : $8.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth